Janssen to Present Results of Imbruvica (ibrutinib)-based Combination Regimen as 1L Treatment for Chronic Lymphocytic Leukemia at ASCO

 Janssen to Present Results of Imbruvica (ibrutinib)-based Combination Regimen as 1L Treatment for Chronic Lymphocytic Leukemia at ASCO

Shots:

  • Janssen to present new data from the fixed-duration cohort of P-II CAPTIVATE study, demonstrating 95% of patients treated with combined Imbruvica + Venetoclax were alive and progression-free @2yrs. with deep remissions were seen across all subgroups, including patients with high-risk CLL
  • Additionally, Janssen will present 7yrs. data from the RESONATE-2 study on PFS and OS benefits with single-agent Imbruvica, reinforcing the survival benefits and long-term tolerability of therapy for patients with CLL
  • The results of RESONATE-2 study supporting the long-term benefits of Imbruvica monothx. in 1L CLL, supporting the use of Imbruvica as SOC

Click here to­ read full press release/ article | Ref: Janssen | Image: Ars Technica

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post